Andrew Clark Dean

Title(s)HS Associate Clinical Professor, Psychiatry and Biobehavioral Sciences
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Future Oncol. 2025 Feb 12; 1-10. Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Jin Leei W, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. PMID: 39935331.
      View in: PubMed   Mentions:    Fields:    
    2. Smoking, tobacco dependence, and neurometabolites in the dorsal anterior cingulate cortex. Mol Psychiatry. 2023 Nov; 28(11):4756-4765. O'Neill J, Diaz MP, Alger JR, Pochon JB, Ghahremani D, Dean AC, Tyndale RF, Petersen N, Marohnic S, Karaiskaki A, London ED. PMID: 37749232; PMCID: PMC10914613.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 10 07; 402(10409):1272-1281. Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. PMID: 37708904; PMCID: PMC11664154.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    4. Polygenic contributions to performance on the Balloon Analogue Risk Task. Mol Psychiatry. 2023 Aug; 28(8):3524-3530. Nurmi EL, Laughlin CP, de Wit H, Palmer AA, MacKillop J, Cannon TD, Bilder RM, Congdon E, Sabb FW, Seaman LC, McElroy JJ, Libowitz MR, Weafer J, Gray J, Dean AC, Hellemann GS, London ED. PMID: 37582857; PMCID: PMC10618088.
      View in: PubMed   Mentions:
    5. Cognitive training and remediation interventions for substance use disorders: a Delphi consensus study. Addiction. 2023 05; 118(5):935-951. Verdejo-Garcia A, Rezapour T, Giddens E, Khojasteh Zonoozi A, Rafei P, Berry J, Caracuel A, Copersino ML, Field M, Garland EL, Lorenzetti V, Malloy-Diniz L, Manning V, Marceau EM, Pennington DL, Strickland JC, Wiers R, Fairhead R, Anderson A, Bell M, Boendermaker WJ, Brooks S, Bruno R, Campanella S, Cousijn J, Cox WM, Dean AC, Ersche KD, Franken I, Froeliger B, Gamito P, Gladwin TE, Goncalves PD, Houben K, Jacobus J, Jones A, Kaag AM, Lindenmeyer J, McGrath E, Nardo T, Oliveira J, Pennington CR, Perrykkad K, Piercy H, Rupp CI, Schulte MHJ, Squeglia LM, Staiger P, Stein DJ, Stein J, Stein M, Stoops WW, Sweeney M, Witkiewitz K, Woods SP, Yi R, Zhao M, Ekhtiari H. PMID: 36508168; PMCID: PMC10073279.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    6. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 04 10; 41(11):2007-2019. Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M, APACT Investigators. PMID: 36521097; PMCID: PMC10082313.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    7. Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. Lancet Gastroenterol Hepatol. 2022 10; 7(10):943-951. Dean A, Gill S, McGregor M, Broadbridge V, Järveläinen HA, Price T. PMID: 35803294.
      View in: PubMed   Mentions:
    8. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2022 07; 23(7):919-930. Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Gallardo-Rincon D, Blagden S, Brenton J, Perren TJ, Sundar S, Lord R, Dark G, Hall M, Banerjee S, Glasspool RM, Hanna CL, Williams S, Scatchard KM, Nam H, Essapen S, Parkinson C, McAvan L, Swart AM, Popoola B, Schiavone F, Badrock J, Fananapazir F, Cook AD, Parmar M, Kaplan R, Ledermann JA. PMID: 35690073; PMCID: PMC9630160.
      View in: PubMed   Mentions:
    9. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol. 2021 12; 10(12):1550-1563. Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. PMID: 34750990; PMCID: PMC8674005.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    10. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Med. 2021 10; 10(20):7162-7173. Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL. PMID: 34549539; PMCID: PMC8525125.
      View in: PubMed   Mentions:
    11. Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial. BMJ Open Gastroenterol. 2021 06; 8(1). Luo H, Galvão DA, Newton RU, Tang C, Dean A, Jasas K, Johansson M, Yusoff I, Spry N, Taaffe DR. PMID: 34099463; PMCID: PMC8186755.
      View in: PubMed   Mentions:
    12. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer. 2021 07; 151:14-24. Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. PMID: 33957442.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    13. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2020 10; 159(1):101-111. Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL. PMID: 32861537; PMCID: PMC8450972.
      View in: PubMed   Mentions:
    14. Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. Clin Colorectal Cancer. 2021 03; 20(1):e21-e34. Travers A, Jalali A, Begbie S, Semira C, Kosmider S, Ananda S, Wong R, Lee M, Shapiro J, Burge M, Yip D, Torres J, Ma B, Nott L, Dean A, Tie J, Khattak A, Lim S, Wong HL, Gibbs P. PMID: 32919889.
      View in: PubMed   Mentions:
    15. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol. 2020 07; 21(7):969-977. Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, James EC, White IR, Perren T, Lord R, Dark G, Earl HM, Hall M, Kaplan R, Ledermann JA, Clamp AR. PMID: 32615110; PMCID: PMC7327508.
      View in: PubMed   Mentions:
    16. No significant elevation of translocator protein binding in the brains of recently abstinent methamphetamine users. Drug Alcohol Depend. 2020 Aug 01; 213:108104. London ED, Okita K, Kinney KR, Dean AC, McClintick MN, Rizor EJ, Johnson MC, Mahmoudie T, Brody AL, Nurmi EL, Seaman LC, Farahi J, Ginder N, Mandelkern MA. PMID: 32570138; PMCID: PMC9059651.
      View in: PubMed   Mentions: 7     Fields:    
    17. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 05; 21(5):710-722. Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. PMID: 32359490; PMCID: PMC8210534.
      View in: PubMed   Mentions:
    18. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. Pancreas. 2020 01; 49(1):62-75. Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. PMID: 31856081; PMCID: PMC6946097.
      View in: PubMed   Mentions:
    19. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019 12 07; 394(10214):2084-2095. Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. PMID: 31791688; PMCID: PMC6902268.
      View in: PubMed   Mentions:
    20. Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. BMJ Case Rep. 2019 Apr 08; 12(4). Das A, Dean A, Clay T. PMID: 30962211; PMCID: PMC6453349.
      View in: PubMed   Mentions:
    21. Cognitive deficit in methamphetamine users relative to childhood academic performance: link to cortical thickness. Neuropsychopharmacology. 2018 07; 43(8):1745-1752. Dean AC, Morales AM, Hellemann G, London ED. PMID: 29704001; PMCID: PMC6006320.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    22. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28; 390(10106):1949-1961. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA, ARIEL3 investigators. PMID: 28916367; PMCID: PMC5901715.
      View in: PubMed   Mentions: 726     Fields:    Translation:HumansCTClinical Trials
    23. Striatal dopamine D1-type receptor availability: no difference from control but association with cortical thickness in methamphetamine users. Mol Psychiatry. 2018 05; 23(5):1320-1327. Okita K, Morales AM, Dean AC, Johnson MC, Lu V, Farahi J, Mandelkern MA, London ED. PMID: 28894300; PMCID: PMC5847392.
      View in: PubMed   Mentions:
    24. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. Biomed Res Int. 2016; 2016:4627214. Dean A, Byrne A, Marinova M, Hayden I. PMID: 27525268; PMCID: PMC4972920.
      View in: PubMed   Mentions:
    25. Midbrain functional connectivity and ventral striatal dopamine D2-type receptors: link to impulsivity in methamphetamine users. Mol Psychiatry. 2016 11; 21(11):1554-1560. Kohno M, Okita K, Morales AM, Robertson CL, Dean AC, Ghahremani DG, Sabb FW, Rawson RA, Mandelkern MA, Bilder RM, London ED. PMID: 26830141; PMCID: PMC4970974.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    26. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 06; 387(10018):545-557. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT, NAPOLI-1 Study Group. PMID: 26615328.
      View in: PubMed   Mentions:
    27. Midbrain dopamine D2/D3 receptor availability and drug craving are associated with mesocorticolimbic gray matter volume in methamphetamine users. Mol Psychiatry. 2015 Jun; 20(6):658. Morales AM, Kohno M, Robertson CL, Dean AC, Mandelkern MA, London ED. PMID: 25993553.
      View in: PubMed   Mentions:
    28. Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users. Mol Psychiatry. 2015 Jun; 20(6):764-71. Morales AM, Kohno M, Robertson CL, Dean AC, Mandelkern MA, London ED. PMID: 25896164; PMCID: PMC4440838.
      View in: PubMed   Mentions:
    29. Denial in methamphetamine users: Associations with cognition and functional connectivity in brain. Drug Alcohol Depend. 2015 Jun 01; 151:84-91. Dean AC, Kohno M, Morales AM, Ghahremani DG, London ED. PMID: 25840750; PMCID: PMC4447566.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    30. Effects of the Youth Empowerment Seminar on impulsive behavior in adolescents. J Adolesc Health. 2013 Jul; 53(1):139-41. Ghahremani DG, Oh EY, Dean AC, Mouzakis K, Wilson KD, London ED. PMID: 23601502.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    31. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug Alcohol Depend. 2013 Jun 01; 130(1-3):245-8. Hallock RM, Dean A, Knecht ZA, Spencer J, Taverna EC. PMID: 23265089.
      View in: PubMed   Mentions:
    32. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology. 2013 Jan; 38(2):259-74. Dean AC, Groman SM, Morales AM, London ED. PMID: 22948978; PMCID: PMC3527116.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansAnimals
    33. White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology (Berl). 2010 Mar; 209(1):13-24. Tobias MC, O'Neill J, Hudkins M, Bartzokis G, Dean AC, London ED. PMID: 20101394; PMCID: PMC2819660.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    34. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend. 2009 Nov 01; 105(1-2):48-55. Dean AC, London ED, Sugar CA, Kitchen CM, Swanson AN, Heinzerling KG, Kalechstein AD, Shoptaw S. PMID: 19608354; PMCID: PMC2754143.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    35. Examination of the impact of ethnicity on the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Fake Bad Scale. Clin Neuropsychol. 2008 Dec; 22(6):1054-60. Dean AC, Boone KB, Kim MS, Curiel AR, Martin DJ, Victor TL, Zeller MA, Lang YK. PMID: 18609316.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Frameless stereotactic placement of depth electrodes in epilepsy surgery. J Neurosurg. 2005 Jun; 102(6):1040-5. Mehta AD, Labar D, Dean A, Harden C, Hosain S, Pak J, Marks D, Schwartz TH. PMID: 16028763.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    Andrew's Networks
    Concepts (194)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California